Placebo News and Research

RSS

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.

17 Oct 2018

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratorios S.A. which has a business foundation in Latin America.

16 Oct 2018

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier--which keeps large molecules in the blood from entering the brain--becomes abnormally permeable, allowing fibrin to leak into the brain and trigger inflammation.

16 Oct 2018

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.

12 Oct 2018

Researchers identify effective ketamine dosage levels for patients with treatment-resistant depression

A study led by Massachusetts General Hospital investigators identifies two subanesthetic dosage levels of the anesthetic drug ketamine that appear to provide significant symptom relief to patients with treatment-resistant depression.

11 Oct 2018

Chewing gum could be a strategy to help reduce vitamin deficiency

Nearly 15 percent of all chewing gum varieties sold promise to provide health-enhancing supplements to users, so Penn State researchers studied whether two vitamin-supplemented products were effective at delivering vitamins to the body. Their results validate the concept of gum as an effective delivery system for at least some vitamins.

10 Oct 2018

Researchers create open access database on healthy immunity

Researchers have created a freely available database of healthy human immunity that can serve as an instant comparison group in immune system studies.

9 Oct 2018

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

8 Oct 2018

Diet and weight may influence response to bipolar disorder treatment, shows study

Data from a clinical trial has shown that how people respond to treatment for Bipolar Disorder may be influenced by their weight and the overall quality of their diet, including whether they are eating a diet high in foods thought to contribute to general inflammation.

8 Oct 2018

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising results of the T-CALM Phase 2 clinical trial of its first-in-class T-type calcium channel modulator CX-8998 in essential tremor.

7 Oct 2018

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

Boehringer Ingelheim and Eli Lilly and Company today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.

5 Oct 2018

New approach could lead to precise treatments for traumatic brain injury

Traumatic head injury can have widespread effects in the brain, but now scientists can look in real time at how head injury affects thousands of individual cells and genes simultaneously in mice.

5 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that the appetite-suppressant drug lorcaserin decreases risk of developing diabetes and increases the rates of remission of high blood sugar.

4 Oct 2018

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

At the 2018 Meeting of the European Association for the Study of Diabetes, Brigham and Women's Hospital investigators from the Thrombolysis in Myocardial Infarction Study Group presented diabetes-related findings from CAMELLIA-TIMI 61, a clinical trial of overweight and obese patients designed to test lorcaserin, a weight loss drug manufactured by the trial's sponsor, Eisai Inc.

4 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam in spinal muscular atrophy.

3 Oct 2018

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

New research presented at the annual meeting of the European Association for the Study of Diabetes and published simultaneously in The Lancet Diabetes & Endocrinology shows how the glucose-lowering drug lixisenatide can slow or prevent damage to the kidneys in macro-albuminuric patients with type 2 diabetes mellitus and cardiovascular disease.

3 Oct 2018

Human clinical trial of investigational calcification inhibitor generates promising results

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.

3 Oct 2018

Placebo News and Research

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

Researchers identify effective ketamine dosage levels for patients with treatment-resistant depression

Chewing gum could be a strategy to help reduce vitamin deficiency

Researchers create open access database on healthy immunity

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Diet and weight may influence response to bipolar disorder treatment, shows study

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

New approach could lead to precise treatments for traumatic brain injury

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

Human clinical trial of investigational calcification inhibitor generates promising results

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News